Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
RELATIVITY-020 trial: what clinicians have said so far
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
- NCT01968109 ↗
- Completed
- Bristol-Myers Squibb
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on RELATIVITY-020 (relatlimab plus nivolumab; relatlimab; BMS-986213 in advanced solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RELATIVITY-020 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 YouTube videos | |
| 6 podcast episodes | |
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- Neoplasms by Site
- Interventions
- Relatlimab; Nivolumab; BMS-986213
- Arms
- Relatlimab · Experimental
- Relatlimab + Nivolumab · Experimental
- BMS-986213 · Experimental
- Enrollment
- 1,482
- Primary outcomes
- Number of Participants With Adverse Events, Deaths and Clinically Relevant Laboratory Abnormalities
- Part C, D1, D2, E - Objective Response Rate Per BICR
- Part C, D1, D2, E - Disease Control Rate (DCR) Per BICR
- Part C, D1, D2, E - Duration of Response (DOR) Per BICR
- Part D1: Number of Participants With Adverse Events in the Broad Scope Standardized MedDRA (SMQ) Anaphylactic Reaction Occurring Within 2 Days of Any Doses of Study Therapy
- Part C, D1, D2, E - Objective Response Rate Per BICR
- Sponsor
- Bristol-Myers Squibb
- Start
- Nov 5, 2013
- Primary completion
- May 22, 2024
- Results posted
- Yes
- Registry record
- NCT01968109 · updated Apr 6, 2026
Publications
linked from the registry- Ascierto PA, Tang H, Dolfi S, Nyakas M, Marie Svane I, Munoz-Couselo E, Grob JJ, Gomez-Roca CA, Chiarion-Sileni V, Peltola K, Larkin J, Melero I, Callahan M, Dummer R, Djidel P, Warad D, Reusser-Wolf D, Lipson EJ, Garnett-Benson C. Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020. J Immunother Cancer. 2025 Feb 25;13(2):e009773. doi: 10.1136/jitc-2024-009773. PubMed 40010775
- Ascierto PA, Lipson EJ, Dummer R, Larkin J, Long GV, Sanborn RE, Chiarion-Sileni V, Dreno B, Dalle S, Schadendorf D, Callahan MK, Nyakas M, Atkinson V, Gomez-Roca CA, Yamazaki N, Tawbi HA, Sarkis N, Warad D, Dolfi S, Mitra P, Suryawanshi S, Grob JJ. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. J Clin Oncol. 2023 May 20;41(15):2724-2735. doi: 10.1200/JCO.22.02072. Epub 2023 Feb 13. PubMed 36780608
- Huuhtanen J, Kasanen H, Peltola K, Lonnberg T, Glumoff V, Bruck O, Dufva O, Peltonen K, Vikkula J, Jokinen E, Ilander M, Lee MH, Makela S, Nyakas M, Li B, Hernberg M, Bono P, Lahdesmaki H, Kreutzman A, Mustjoki S. Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma. J Clin Invest. 2023 Mar 15;133(6):e164809. doi: 10.1172/JCI164809. PubMed 36719749
- Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Coexisting Alterations of MHC Class I Antigen Presentation and IFNgamma Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy. Cancer Immunol Res. 2022 Oct 4;10(10):1254-1262. doi: 10.1158/2326-6066.CIR-22-0326. PubMed 35969233